TYBR Health has announced the first US clinical use of the collagen-based tissue protector, B3 GEL System, aimed at supporting post-surgical healing.
The flowable gel system’s clinical use was initiated by Dr Hanna Tammam, a fellowship-trained hand, elbow, and shoulder surgeon based in Lubbock, Texas.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The B3 GEL System is derived from the extracellular matrix (ECM). Unlike conventional physical barriers that may be challenging to position within tight anatomical areas, it offers a flowable format that conforms to tissue surfaces.
It maintains biomechanical separation throughout the essential healing window before being naturally resorbed by the body.
TYBR Health is actively monitoring the system’s performance through ongoing real-world clinical use and post-market surveillance.
The company plans to extend the clinical use of the B3 GEL System in partnership with surgeons and will continue collecting evidence on its performance and patient outcomes through post-market surveillance studies across surgical environments.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIt is cleared by the US Food and Drug Administration (FDA) to support the protection of soft tissues during post-surgical healing processes.
TYBR Health chief commercial officer Chris Wright said: “The first cases in the US with the B3 GEL System represent a pivotal milestone for TYBR Health and for patients undergoing musculoskeletal surgeries.
“These initial procedures mark the transition from regulatory clearance to real-world clinical application, allowing surgeons to directly address post-surgical tissue tethering—a complication that too often limits patient mobility and extends recovery times.
“By protecting healing tissues during the critical early phase, B3 GEL helps bridge the gap between surgical repair and functional success, enabling patients to regain movement faster and more completely.”
In June 2025, the FDA granted 510(k) clearance to TYBR Health’s bioresorbable B3 GEL system, a barrier intended for protecting healing tissues and preserving mobility post-surgery, which involved ligaments, tendons, and skeletal muscle.
